Intestinal mucosa inflammation pathways

The intestinal mucosa contains epithelial cells that form a critical barrier between luminal microbes and underlying immune cells. Chronic intestinal inflammation arises when this barrier integrity is compromised due to dysregulated signaling involving multiple molecular players. Key among them are receptor-interacting protein kinases RIPK1 and RIPK2 which regulate programmed cell death and microbial sensing respectively. The NF-kappaB pathway plays an essential role by controlling transcriptional responses during TNF stimulation. Genetic variations affecting proteins such as A20 (TNFAIP3) can exacerbate susceptibility by failing to properly restrain inflammatory signals leading to excessive epithelial apoptosis, erosion, ulceration, crypt abscesses characteristic of IBD pathology. Understanding these intertwined molecular networks has guided development of targeted therapies aimed at restoring balance between protective immunity and pathological inflammation. In summary, "Intestinal mucosa inflammation pathways" represent an integrated network crucial for maintaining gut homeostasis whose dysregulation underlies major gastrointestinal diseases but does not correspond directly to one canonical therapeutic target molecule or receptor.

Other names

Inflammatory bowel disease-related signaling pathwaysIntestinal epithelial cell inflammatory signalingMucosal immune response pathways

Mechanisms vary depending on specific targets within these pathways: Blocking pro-inflammatory cytokines like TNF-alpha reduces epithelial cell death. Inhibiting kinases such as RIPK1/RIPK2 modulates cell death and microbial sensing. Modulation of NF-kappaB pathway affects transcription of genes driving inflammation. These drugs act on specific molecules within these broader inflammatory cascades rather than on "intestinal mucosa inflammation pathways" per se.